

Cite this: *Chem. Sci.*, 2026, 17, 3894

All publication charges for this article have been paid for by the Royal Society of Chemistry

The hidden language of gut-derived lipopolysaccharides: fine chemistry, huge immunological consequences

Marcello Mercogliano,^a Valentina Mazziotti,^{ab} Alba Silipo,^{id}^{ab} Antonio Molinaro^{id}^{ab} and Flaviana Di Lorenzo^{id}^{*ab}

Lipopolysaccharides (LPSs) from Gram-negative bacteria are traditionally viewed as potent “endotoxins” recognized by the immune system and capable of triggering robust inflammation. However, increasing evidence from gut commensals is dismantling this one-dimensional view. The gastrointestinal tract is indeed the major reservoir of LPSs, owing to the dense Gram-negative community inhabiting the small and large intestine, with total weight in healthy individuals estimated to exceed one gram. This necessarily means that the mere presence of LPSs cannot be directly linked to inflammation. Moreover, chronic exposure to low-potency or atypical LPSs can recalibrate innate immunity, fostering tolerance or, conversely, failing to provide adequate tonic stimulation and thereby predisposing the system to aberrant activation. Understanding this delicate balance and the structural and cellular mechanisms that sustain it, is essential to interpret the immunological impact of the gut LPSs in health and disease. In this Perspective, we highlight recent advances revealing the remarkable chemical diversity of commensal-derived LPSs and illustrate how subtle variations in LPS lipid A acylation and phosphorylation, core oligosaccharide architecture, O-antigen composition, and overall supramolecular organization profoundly rewire receptor usage and downstream immune outcomes. These insights underscore the enormous, still largely untapped potential of gut LPS chemistry to reveal unifying structural hallmarks that distinguish inflammatory, tolerogenic, and immunologically “tuned” features. Although fragments of this logic are beginning to emerge, a comprehensive framework remains urgently needed. Decoding the chemical language adopted by LPSs in the gut will be essential to reclassify LPSs not merely as dangerous molecules, but as a potential source of immunomodulators and as a blueprint for next-generation tools enabling precision control of host–microbe interactions.

Received 17th December 2025
Accepted 4th February 2026

DOI: 10.1039/d5sc09900e

rsc.li/chemical-science

^aDepartment of Chemical Sciences and Task Force for Microbiome Studies, University of Naples Federico II, Via Cinthia 4, Naples, 80126, Italy. E-mail: flaviana.dilorenzo@unina.it

^bCEINGE Biotecnologie Avanzate Franco Salvatore, Via Gaetano Salvatore, 486, Naples, 80131, Italy



Marcello Mercogliano

Marcello Mercogliano is a post-doctoral Research Grant Holder in Prof. Di Lorenzo's group at the Department of Chemical Sciences of the University of Naples Federico II where he obtained his PhD in Chemical Sciences. His expertise spans organic synthesis and the application of NMR and mass spectrometry-based techniques to the study of carbohydrates and glycolipids. His research focuses on elucidating the structural features underlying the immunomodulatory properties of glycoconjugates, with particular interest in their intricate structure–function relationships.



Valentina Mazziotti

Valentina Mazziotti is a post-doctoral Research Grant Holder in Prof. Di Lorenzo group at the Department of Chemical Sciences University of Naples Federico II. She awarded the title of PhD in Neuroscience at the University of Verona after completing studies in Neurobiology at Sapienza University of Rome. Her research focuses on neuropathological mechanisms in neurodegenerative and neuroinflammatory diseases, including multiple sclerosis and Parkinson's disease. Currently, she investigates the gut microbiota–brain axis, analysing the impact of bacterial glycoconjugates from the gut on neuroinflammation.



Introduction

Lipopolysaccharides (LPSs) are major constituents of the outer leaflet of the Gram-negative bacterial outer membrane and key mediators of host-microbe interactions. They are widely regarded as among the microbial molecules with a profound impact on the host immune system.¹ Owing to this central role, LPSs hold considerable promise for translational applications across medicine, immunology, and vaccinology.^{1–3} An LPS exerts its action through interaction with pattern-recognition receptors (PRRs) expressed by innate immune cells, thereby

triggering activation of multiple signal transduction cascades.^{4,5} Among these, the best characterized is the pathway initiated by binding of an LPS molecule to the Toll-Like Receptor 4/Myeloid Differentiation Protein-2 (TLR4/MD-2) complex, which represents the “canonical” axis of LPS sensing.^{1,4,6} Upon binding to the TLR4/MD-2 complex, LPS drives the formation of an activated TLR4/MD-2/LPS dimer, which triggers intracellular signaling, most prominently the NF- κ B cascade, by inducing conformational rearrangements in the Toll/IL-1R (TIR) domains of TLR4 and culminating in the transcription of pro-inflammatory cytokines and immune mediators.⁷ Consequently, based largely on studies of pathogens, LPSs have historically been regarded as potent pro-inflammatory molecules, known as “endotoxins” and considered potential threats to human health.⁸ Nevertheless, and fortunately, the magnitude of the inflammatory response they induce is inextricably linked to their chemical structure.^{9–11} The region of an LPS that primarily engages the TLR4/MD-2 complex is the lipid A: the membrane-anchoring glycolipid consisting of a $\beta(1 \rightarrow 6)$ -linked diglucosamine backbone substituted with phosphate groups (typically at position 4' of the non-reducing glucosamine and at position 1 of the reducing one) as well as acyl chains of varying lengths and number (Fig. 1). Beyond lipid A, a smooth-type LPS (S-LPS) also comprises a heteropolysaccharide composed of the core oligosaccharide (core OS) and the O-polysaccharide domain (or O-antigen). In contrast, when the O-antigen is absent, the molecule is referred to as rough-type LPS (R-LPS) or lipooligosaccharide (LOS) (Fig. 1).¹⁹ Although lipid A represents the immunodominant and most bioactive portion of an LPS, its fine structure varies substantially across species, strains, and even within a single bacterial population.¹ Such variations profoundly influence TLR4 engagement and ultimately dictate



Alba Silipo

Prof. Alba Silipo's research career began with the structural characterization of microbial glycoconjugates using state-of-the-art analytical techniques. She subsequently focused on the conformational analysis of glycoconjugates and on the investigation of protein-ligand interactions by NMR spectroscopy, biophysical and computational approaches. Her current research is centred on elucidating the structure-function relationships of microbial glycoconjugates, with particular emphasis on the integrated use of spectroscopic and biophysical methods to unravel the molecular mechanisms governing protein-carbohydrate interactions at the host-pathogen interface. Prof. Silipo has published more than 200 peer-reviewed articles in international journals.


ships of microbial glycoconjugates, with particular emphasis on the integrated use of spectroscopic and biophysical methods to unravel the molecular mechanisms governing protein-carbohydrate interactions at the host-pathogen interface. Prof. Silipo has published more than 200 peer-reviewed articles in international journals.



Antonio Molinaro

Antonio Molinaro is Full Professor of Organic Chemistry at the Department of Chemical Sciences of University of Naples Federico II. He is also Special Appointed Professor of Organic Chemistry at Osaka University, Department of Chemistry. His laboratories and his group are internationally recognized in Glycoscience. He is an ERC Advanced Grant awardee and Coordinator of MSCA DN projects. Prof. A. Molinaro has published over 300 peer-reviewed papers in international journals.

published over 300 peer-reviewed papers in international journals.



Flaviana Di Lorenzo

Flaviana Di Lorenzo is Associate professor at the Department of Chemical Sciences University of Naples Federico II and CEINGE Institute. She is an ERC Starting Grant awardee and Principal Investigator of other National and International research projects. She is an expert in bacterial glycans structural and functional characterization with special attention to lipopolysaccharides and capsular polysaccharides. Contextually, she

received the Novotny Award 2024, the top global recognition for young investigators in endotoxin research. She is an expert in chemical methodologies, NMR spectroscopy and HR mass spectrometry in the structural glycobiology field. She also has expertise in immunological techniques to assess glycans activity. She published more than 85 papers, leads a group of 6 people (4 PhD students and 2 post-docs), and hosts 3 Master's students in her labs.






Fig. 1 Schematic illustration of the general chemical architecture of an LPS. The structure shown is conceptual and intended solely for illustrative purposes. Zigzag lines in the lipid A region denote the fatty acyl chains, the circled "P" stands for phosphate group.

the strength and quality of the ensuing immune response. The core OS (for R-LPSs) and the O-antigen (for S-LPSs) are the most diverse segments of the molecule and major determinants of antigenic specificity, virulence potential, and the capacity of Gram-negative bacteria to attach to, colonize, or evade the host.^{12,13} These structural domains also contribute to the intrinsic antimicrobial resistance of Gram-negative bacteria by forming a permeability barrier at the outer membrane, underscoring the dual role of LPSs as both immune triggers and a physical shield.^{1,14}

Over the years, therefore, it has become increasingly evident that LPS chemistry and biology are far more complex than initially assumed. The molecular architecture of an LPS is highly variable: each of its domains can differ markedly in chemical composition depending on the bacterial species, environmental cues, and host-associated factors. These structural variations not only allow bacteria to adapt and thrive in specific niches, but also profoundly reshape immune recognition by engaging a broad spectrum of receptors and signaling pathways. Consequently, LPS molecules can elicit remarkably diverse immunological outputs, ranging from robust inflammatory responses to weak activation or even complete immunological silence.^{9,15} Despite decades of investigation, the mechanisms by which different LPS structures trigger, or suppress, innate immune responses remain only partially understood. What is becoming increasingly evident, however, is the existence of a complex interaction network in which a given LPS engages multiple immune receptors, challenging the classical view of TLR4 as the sole, or even primary, sensor in all contexts.^{6,16} This underscores an urgent need to delineate how an LPS, on the basis of its structural characteristics, engages alternative signaling pathways that, although still poorly characterized, may play crucial roles in fine-tuning immune responses.⁶ Identifying the key structural determinants and related signaling pathways activated is essential for developing new biomedical strategies with far-reaching implications for human health. Yet, despite this tremendous biomedical potential, the structure–function landscape of LPSs still remains surprisingly underexplored, representing one of the most pressing and promising frontiers in (glyco)immunology. One reason for this knowledge gap is that, to date, most studies have disproportionately focused on the pro-inflammatory activity of LPSs, often using *Escherichia coli* LPS as

a representative model for the entire class. In contrast, far less attention has been devoted to LPSs from non-pathogenic bacteria, including those that inhabit our intestines, *i.e.* the gut microbiota. This microbial community, densely populated and highly diverse, plays a central role in host physiology, supporting nutrient digestion, metabolite production, metabolic regulation, and, critically, the development and calibration of the immune system.¹⁷ A continuous bidirectional dialogue between microbiota and host immunity dictates whether responses remain tolerogenic or shift toward inflammation. When this equilibrium is perturbed, a state referred to as dysbiosis, microbiota–immune interactions can skew toward pathology,^{18–20} contributing to metabolic disorders such as obesity and type 2 diabetes,²¹ chronic inflammatory diseases,²² autoimmune conditions,^{23,24} and allergy.²⁵ Within this framework, a central question in (glyco)immunology emerges: how are commensal and mutualistic bacteria recognized by the immune system, and how do their LPSs guide the immune system toward homeostasis rather than inflammation? Indeed, circulating gut-derived LPSs can be detected in healthy individuals without triggering overt inflammation,²⁶ thus further highlighting that not all LPSs are created equal. Their chemical structures and, consequently, the receptors they engage dictate whether they promote tolerance, immune education, or pathology. This highlights the need to reevaluate the statement that circulating LPSs directly cause inflammatory responses. But then, what is the role of non-inflammatory LPSs? Are they merely passive molecular bystanders, active modulators of immune tone, or unrecognized contributors to immune training and disease susceptibility? And, given their abundance and capacity to tune immune responses, should certain gut-derived LPSs be considered potential postbiotics rather than “endotoxins”?

This Perspective aims to spotlight the chemical and biological significance of recently characterized “harmless” LPSs expressed by gut commensals. We examine how their structural features underpin unconventional immunomodulatory activities and summarize what is currently known, and still unresolved, about the signaling pathways they engage. Deciphering these mechanisms and the structural determinants that shape specific immune outcomes will be crucial for identifying new therapeutic targets and for developing selective immunomodulators with translational potential.

Beyond the pro-inflammatory paradigm: the case of *Bacteroides* spp. LPSs

A growing body of evidence shows that many commensal and mutualistic bacteria produce LPS variants whose molecular architecture is tuned to promote immune tolerance rather than inflammation.^{9,27} Although a unified framework for distinguishing pro-inflammatory from “tolerogenic” LPSs is still lacking, emerging patterns are remarkably consistent: hypoacylation and reduced phosphorylation in the lipid A are commonly found in microbiota-derived lipid A and correlated



with weakened TLR4 engagement and attenuated signaling.⁹ This is particularly evident in *Bacteroides* species (Fig. 2). Despite the limited number of fully elucidated structures, *Bacteroides* spp. remain one of the most intriguing, and widespread, sources of immunomodulatory LPSs within the human gut.²⁸ As dominant early colonizers, they contribute to gut ecological stability through nutrient biosynthesis, metabolic cooperation, toxin neutralization, and competitive exclusion of pathogens.^{29–32} Across the genus, including *B. vulgatus*, *B. eggerthii*, *B. dorei*, *B. fragilis*, and *B. thetaiotaomicron* and others, LPS lipid A structures consistently depart from the canonical hexa-acylated blueprint of *E. coli* (Fig. 2). Missing acyl chains and, in some cases, reduced phosphorylation impede the precise “lock-and-key” interactions required to stabilize the TLR4/MD-2 heterotetramer. Without this stabilization the full downstream signaling is compromised, resulting in markedly attenuated or entirely absent pro-inflammatory responses.

The case of *B. vulgatus* (recently reclassified as *Phocaeicola vulgatus*) illustrates this principle with exceptional clarity. Its LPS lipid A consists of a mixture of tetra- and penta-acylated species carrying a single phosphate group at position 1 of the reducing glucosamine (Fig. 2).^{33,34} The absence of the 4' phosphate, known to reduce endotoxic activity by up to two orders of magnitude,³⁵ further contributes to the weak agonistic profile of

this LPS. Notably, no additional negative charge sources are found in this LPS apart from the phosphate group on the 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) unit (the “sugar marker” of LPS molecules), further contributing to the weak receptor engagement and subsequent inflammatory signaling activation. Consistently, experimental studies demonstrated that *B. vulgatus* LPS elicits minimal pro-inflammatory cytokine release in human dendritic cells while promoting elevated anti-inflammatory IL-10 production, a hallmark of tolerogenic immune engagement.³³ This was an unprecedented observation for an LPS molecule and became even more compelling in light of *in vivo* findings showing that, in mouse models of colitis, *B. vulgatus* LPS alleviates intestinal inflammation by inducing a distinct form of LPS tolerance.³⁶ Mechanistically, this effect appears to operate through the TLR4/MD-2 axis in lamina propria CD11c⁺ cells, pointing to a specialized, tissue-adapted tolerogenic response driven by this commensal-derived LPS.³⁶ While lipid A provides the primary determinant of attenuated TLR4 activation, unusual features in the saccharide region of *B. vulgatus* LPS add further layers of complexity. Notably, as shown in Fig. 3, the core OS lacks the heptose residue typically found directly linked to the Kdo unit. In heptose-deficient LPS, this position is commonly occupied by an α -mannose residue; however, in *B. vulgatus* it is instead replaced by a 6-deoxy- α -




Fig. 2 Comparison between *E. coli* and *Bacteroides* spp. lipid A structures. *E. coli* lipid A displays the classical TLR4 agonistic architecture, consisting of a bis-phosphorylated glucosamine disaccharide backbone bearing six acyl chains of 12 and 14 carbon atoms arranged in a 4 + 2 distribution. In contrast, *Bacteroides* spp. lipid A species are highly heterogeneous and typically feature a single phosphate group and four or five acyl chains with lengths ranging from 15 to 17 carbon atoms, organized in a 3 + 2 distribution. Owing to the coexistence of lipid A species differing in acyl chain length, the structure depicted represents the predominant species for illustrative purposes. The lipid A from *B. fragilis* is also decorated by a *PEtN* and/or hexuronic acid not reported in the figure as their location remains to be defined. Pink color indicates non-stoichiometric substitution of acyl chains.



mannose, an α -rhamnose. The occurrence of rhamnose at this position is not an isolated peculiarity, but rather a conserved feature shared by all *Bacteroides* LPS structures characterized to date, with the exception of *B. thetaiotaomicron* (Fig. 3).³⁷ The functional significance of this conserved substitution remains unknown, but its recurrence strongly suggests an evolutionarily selected role for its glycosyltransferase. However, it is also tempting to speculate that α -rhamnose may represent an early structural cue of a core OS configured for non-canonical receptor engagement. Adding further interest, this rhamnose residue is itself substituted with another highly unusual sugar for LPS core regions: β -galactofuranose (Fig. 3). Strikingly, galactofuranose has also been identified in the core OS of *B. eggerthii* and *B. dorei* (now *Phocaeicola dorei*), whose complete structural elucidation has only recently been achieved (Fig. 3).^{38,39} As observed for rhamnose, galactofuranose appears to be a recurring feature of *Bacteroides* LPS core OSs, again with the exception of *B. thetaiotaomicron*, suggesting a non-random and potentially functional role that warrants further investigation. One plausible hypothesis is that galactofuranose acts as a molecular signal that biases host immune recognition toward a more tolerogenic program, thereby enhancing bacterial fitness within the intestinal environment.³⁶ In this frame, it has been shown that the C-type lectin DC-SIGN, expressed on dendritic cells and regulatory M2 macrophages,⁴⁰ recognizes

specific epitopes within the *B. vulgatus* LPS structure, thus possibly playing a key role in shaping immune responses. Unlike TLR4, this lectin does not directly activate NF- κ B, while it modulates TLR-dependent signaling and can skew responses toward IL-10 production, anti-inflammatory programs, and tissue repair when engaged by particular glycan signatures,^{41–43} including those present in *B. vulgatus* LPS.^{33,44} Supporting this view, an elegant study using synthetic fragments of *B. vulgatus* LPS revealed that several core OS residues, not only galactofuranose but also fucose, galactose, and Kdo, contribute to DC-SIGN recognition.⁴⁴ More recently, an integrated approach combining chemical synthesis of core OS derivatives, STD Nuclear Magnetic Resonance (NMR) spectroscopy, and molecular simulations elucidated the structural determinants underlying this interaction.⁴⁵ The study demonstrated that fucosylated ligands play a dominant role through a specific fucose-calcium coordination and a subsequent hydrogen-bonding network within the DC-SIGN carbohydrate-recognition domain.⁴⁵ However, galactofuranose further modulates the conformation and presentation of the binding epitope, fine-tuning receptor engagement.⁴⁵ These insights highlight a finely tuned glycan-lectin code and reinforce the need to pinpoint the minimal structural motifs capable of driving such immunomodulatory effects. Adding another layer of complexity to an already intricate signaling landscape, *B.*




Fig. 3 Similarities and differences in *Bacteroides* spp. LPS core OS moieties. In the figure is represented only one of the proposed four structures of the *B. dorei* core OS due to the substitution flexibility of 3,4- α -L-rhamnose which accommodates either β -L-rhamnose or β -L-fucose at the O-3 position. The dotted lines indicate non-stoichiometric substitution. Colors follow the Symbol Nomenclature for Glycans (SNFG) to enable rapid identification of sugar configurations: green for *manno*-, blue for *gluco*-, and yellow for *galacto*-configured sugar units. Kdo is depicted in yellow, while fucose residues are shown in red, in accordance with SNFG conventions.



vulgatus LPS has also been shown to activate TLR2 in addition to modulating TLR4. Using human embryonic kidney (HEK)293 cells engineered to co-express human TLR4 and TLR2, it was observed that *B. vulgatus* LPS induces stronger NF- κ B activation than in cells expressing either receptor alone, suggesting a cooperative or synergistic signaling mechanism.³³ As a matter of fact, the formation of TLR2/TLR4 heterodimers in response to non-canonical LPS structures has been already proposed by Francisco *et al.*⁴⁶ whose molecular docking analyses of LPS from the human opportunistic pathogen *Ochrobactrum intermedium* predicted a favorable TLR2/TLR4/MD-2 heterodimeric interface, a configuration subsequently validated experimentally by fluorescence resonance energy transfer in live cells.⁴⁶ Notably, the uncommon core OS structure of *O. intermedium* LPS emerged as a key contributor to this interaction, further highlighting how subtle chemical features in LPSs can diversify receptor engagement and downstream immune signalling.⁴⁶ However, whether *B. vulgatus* LPS can actually induce TLR2/TLR4 heterodimerization, and through which structural features, remain unresolved. Of note, other *Bacteroides* LPSs, such as *B. eggerthii* LOS and *B. dorei* LPS, also show weak inflammatory profiles and only limited TLR4 activation, even though *B. eggerthii* contains minor lipid A species further decorated with an additional phosphate and an aminoethyl group (Fig. 2).³⁸ Yet, despite sharing the same dominant lipid A species and carrying non-canonical core OS signatures, *i.e.* they express fucose, galactofuranose, and rhamnose, these LPS molecules appear unable to trigger TLR2 signaling. Though, it should be noted that functional assays in cellular systems co-expressing both TLR2 and TLR4 have not yet been performed for these LPSs, and such studies will be essential to clarify receptor usage and to unravel the principles governing this intriguing signaling divergence.

One important member of the *Bacteroides* genus is *B. fragilis*, which constitutes 1–2% of the normal intestinal microflora.^{47,48} It plays multiple roles within the host, largely due to the production of diverse bioactive molecules, including a peculiar LPS and several capsular polysaccharides such as polysaccharide A, both of which have drawn considerable attention for their immunological relevance.^{49–52} Beyond the typical hypo-acylated and mono-phosphorylated lipid A species shared across *Bacteroides* spp., Yang and co-workers recently provided a near-complete characterization of the *B. fragilis* core OS using top-down and tandem mass spectrometry (MS), showcasing the power of this analytical approach.⁵⁰ Their work revealed a complex core OS architecture extending from Kdo and comprising polygalactose and deoxy-hexoses, with potential hexuronic acid residues and 2-aminoethyl phosphate (PEtN) modifications on the lipid A moiety.⁵⁰ The immunological behavior of *B. fragilis* LPS closely mirrors that of *B. vulgatus*. *In vitro*, it suppresses cytokine production in THP-1 monocytes and human dendritic cells, displaying markedly reduced immunostimulatory activity compared to *E. coli* LPS and, under certain conditions, even functioning as a TLR4 antagonist.^{51,52} In collagen antibody-induced arthritis models, *B. fragilis* LPS showed a significantly diminished capacity to induce disease and could even prevent its development when administered at

higher doses.⁵² Additional evidence in healthy mice and *E. coli* LPS-primed mice confirmed these effects: *B. fragilis* LPS lowered TNF- α levels, increased IL-10 release, restored regulatory T-cell populations, without amplifying NF- κ B signaling.^{51,53} Nevertheless, the precise molecular epitopes underlying this behavior remain undefined, highlighting the need for structure to function studies of this characteristic LPS.

Famous, and perhaps even more intriguing than *B. fragilis* and *B. vulgatus*, is *B. thetaiotaomicron*, a deeply studied human gut symbiont capable of producing at least eight distinct capsular polysaccharides that directly shape host–microbe crosstalk, although the underlying mechanisms remain incompletely understood. The first structural elucidation of *B. thetaiotaomicron* LOS was achieved using a mutant strain in which all gene clusters encoding the extensive capsular polysaccharide layer had been deleted.^{37,54,55} This strategy revealed an unprecedented LOS architecture that diverges radically from previously characterized core OS structures: two complex oligosaccharide branches emanating from an α -mannose linked to Kdo and incorporating uronic acids, PEtN, and an uncommon non-acylated glucosamine residue that locally modulates charge (Fig. 3).³⁷ Such an arrangement generates a finely tuned electrostatic landscape that might represent a charge-masking strategy adopted by bacteria to persist in the colonized host.⁵⁶ Although this structural characterization provides a compelling blueprint, it is based on a CPS-deficient mutant; confirming whether the same LOS is produced in the wild-type strain will be an important future step, despite the considerable challenges posed by its dense and heterogeneous capsule repertoire. Crucially and in contrast to *B. vulgatus*, *B. eggerthii*, and *B. dorei*, *B. thetaiotaomicron* lacks galactofuranose and fucose in its LPS, and does not feature α -rhamnose as the sugar immediately following Kdo (Fig. 3), likely underscoring a distinct mechanism underlying its immunomodulatory behavior, which was associated, also in this case, with an attenuated TLR4 activation, engaging of TLR2 pathways, while selectively shaping cytokine profiles.³⁷

Taken together, the case of *Bacteroides* spp. LPSs highlights that, despite architectural diversity, certain structural themes, such as lipid A hypo-acylation, reduced phosphorylation, and specific core OS signatures, recur across species and consistently align with attenuated or tolerogenic immune profiles.⁵⁷ Yet, key comparative experiments are still missing, and the field lacks a unifying structure–function framework capable of predicting immunological behavior across *Bacteroides* spp. LPSs. This motivates extending the analysis to other *Bacteroides* to explore whether other LPSs from this complex and highly heterogeneous genus converge on similar molecular solutions, or reveal new strategies, to shape the inflammatory landscape.

Location matters? Niche-dependent chemistry of microbiota-derived LPS


Atypical LPSs are widespread among Gram-negative members of the gut microbiota characterized thus far, reflecting the profound selective pressure exerted by the host environment,



which shapes both bacterial physiology and LPS architecture. A striking example of this phenomenon is *Veillonella parvula*, a bacterium commonly found in the oral cavity and gastrointestinal tract. Although generally a commensal, it can become opportunistic under conditions of dysbiosis or inflammation.^{58–60} A recent work revealed that two strains, DSM 2008 (intestinal) and 118(3) (oral), produce chemically distinct LPS molecules, despite belonging to the same species.⁶¹ NMR and MS analyses uncovered deep structural divergence: DSM 2008 synthesizes an LPS with an unprecedented O-antigen repeating unit, whereas strain 118(3) produces a LOS characterized by striking heterogeneity in its lipid A. DSM 2008 displays a relatively homogeneous lipid A enriched in hexa-acylated, mono- and bis-phosphorylated species with linear acyl chains, features typically associated with strong TLR4 agonists (Fig. 4). In contrast, strain 118(3) exhibits extraordinary lipid A heterogeneity, ranging from tetra- to hexa-acylated forms, variable phosphorylation states, and a high abundance of branched acyl chains (Fig. 4).⁶¹ Finding two lipid A architectures so profoundly different within the same species, especially considering that lipid A is traditionally regarded as the most conserved region of an LPS molecule, is remarkable and strongly suggests a major influence of the ecological niche from which each strain was isolated (intestine vs. oral cavity). In this frame, bioinformatic and chemical biology approaches will be pivotal to understanding how such extensive structural remodeling arises in strain 118(3). As expected, this lipid A complexity has dramatic consequences for TLR4 activation: the LOS from the oral strain acts as a very weak TLR4 agonist, whereas the intestinal DSM 2008 LPS elicits a noticeably stronger response, though still weaker than *E. coli* LPS, in line with the atypical acyl chain lengths (*i.e.* C13 in place of C14 of *E. coli* LPS). Adding yet another layer of complexity, immunological assays revealed that despite being a potent TLR4 activator in reporter cells, the intestinal LPS induces lower TNF- α release in dendritic cells, behaving overall as a weak inflammatory molecule.⁶¹ This unexpected behavior was attributed to the presence of a highly unusual mannitol-containing tetrameric O-antigen repeating unit, found exclusively in the intestinal strain, composed of β -D-galactofuranose, β -D-galactopyranose, and α -D-glucosamine, polymerised through a phosphodiester linkage between O-6 of mannitol and O-3 of α -D-glucosamine (Fig. 5). This O-antigen is unprecedented not only for incorporating galactofuranose and mannitol phosphate, but also for its zwitterionic character, arising from the coexistence of a phosphate group and a free amino function within the repeating unit. Such zwitterionic motifs have previously been shown to modulate dendritic cell responses in other gut-derived polysaccharides, suggesting that the charge distribution of this O-antigen may directly contribute to its immunomodulatory effect and warrants further investigation. In parallel, intestinal lectins such as DC-SIGN, Langerin, and the Mannose Receptor exhibited markedly stronger binding to the intestinal LPS than to the oral LOS, supporting the notion that C-type lectins may cooperate with TLR4 to fine-tune downstream signaling and steer immune responses toward either activation or tolerance.⁶¹ In this context, future experiments using targeted antagonists

or inhibitors to block C-type lectins and/or TLR4 will be essential to definitively demonstrate the regulatory contribution of the DSM 2008 O-antigen. Overall, beyond underscoring the importance of bacterial niche in shaping LPS chemistry, this study clearly highlighted that the perception of complex molecules such as *V. parvula* LPS relies on the activation of multiple, interdependent pathways that may converge at different nodes to shape the final immune outcome.

A comparable scenario is observed for *Alcaligenes faecalis*, a peculiar Gram-negative commensal known to colonize Peyer's patches, a major gut-associated lymphoid tissue in the small intestine.⁶² *A. faecalis* persists within these immunologically active niches, where it contributes to mucosal homeostasis by protecting the epithelial surface from pathogen invasion, regulating dendritic cell activation, and promoting IgA production through an IL-6-dependent mechanism.⁶³ Its ability to induce IgA secretion enables *A. faecalis* to persist in Peyer's patches by evading excessive immune surveillance, thereby avoiding the pathological inflammation typically associated with enterobacterial LPSs while still supporting mucosal monitoring.^{63,64} Remarkably, its LPS was shown to enhance IgA production without eliciting a strong TLR4 response, a rare combination of features that aligns with the key hallmarks sought in next-generation vaccine adjuvants.⁶⁵ Consistent with this profile, synthetic analogues of its lipid A demonstrated excellent safety and potent adjuvanticity when co-administered intranasally or subcutaneously with antigens in murine models,⁶⁶ enhancing OVA-specific IgG titers and preferentially skewing the response toward Th17 rather than Th1/Th2 immunity.⁶⁷ Moreover, when delivered intranasally together with pneumococcal surface protein A, a universal antigen of *Streptococcus pneumoniae*, the lipid A derivative significantly boosted pneumococcal surface protein A-specific nasal IgA and a protective Th17 response, conferring resistance against pneumococcal challenge.⁶⁶ *A. faecalis* produces both a LOS and an LPS whose structures are far from canonical.⁶⁵ They comprise a heterogeneous mixture of tetra- to hexa-acylated lipid A species, in both mono- and bis-phosphorylated forms, and features 14:0 (3-OH) as the primary and 12:0 (3-OH) and 10:0 as secondary acyl chains (Fig. 4). Even though the hexa-acylated species contain two phosphates and share several acyl chain identities with *E. coli*, multiple structural modifications likely underpin their distinct immunological behavior. Among these, (i) the symmetric acyl-chain distribution (3 + 3 in place of 4 + 2 observed in *E. coli* lipid A), (ii) the presence of a shorter secondary chain (10:0 instead of 14:0) positioned differently relative to *E. coli*, (iii) the inclusion of a hydroxylated secondary acyl moiety, and (iv) the coexistence of hypo-acylated, mono-phosphorylated forms, stand out as particularly relevant (Fig. 4).⁶⁵ Collectively, these features are predicted to weaken TLR4 engagement perturbing the alignment of lipid A within the TLR4/MD-2 pocket, impairing productive dimerization of the receptor complex and ultimately resulting in a poor inflammatory response. Moreover, *A. faecalis* LOS displays a mono-phosphorylated core OS composed of nine monosaccharide units also comprising two *N*-acetyl D-glucosamine, two *N*-acetyl D-galactosamine, one D-glucose, and one D-






Fig. 4 Structural variability in gut commensal lipid As. Owing to the coexistence of lipid A species differing in acyl chain length, the structures depicted represent the predominant species identified in each related study. Pink color indicates non-stoichiometric substitution of acyl chains.

galactose in the outermost region (Fig. 6). This unusual composition tempting suggests that this specific glycan signature might be recognized by lectins expressed in Peyer's patches, potentially contributing to the bacterium ability to persist within this niche. Notably, the Syk-coupled C-type lectin receptor Mincle is expressed in Peyer's patches, where its stimulation by commensal-derived ligands induces IL-6 and IL-23p19 production, thereby regulating intestinal Th17 cells and IL-17-secreting Innate Lymphoid Cells.⁶⁸ This cascade ultimately promotes IgA secretion and supports host-microbiota mutualism while preventing systemic inflammation. Despite some discrepancies in the literature, Mincle has been reported to recognize not only mannose and glucose residues but also galactose and *N*-acetyl galactosamine, both of which are present in the *A. faecalis* core OS (Fig. 6). This raises the intriguing possibility that direct engagement of Mincle by the *A. faecalis* core region contributes to the striking ability of this bacterium to colonize Peyer's patches and sustain a mutually beneficial relationship with the host.

These two examples, *A. faecalis* and *V. parvula*, illustrate a fascinating principle: anatomical niche might be not merely a background variable, but a powerful evolutionary force that sculpts LPS chemistry and, in turn, rewires innate immune recognition. Deciphering this niche–structure–function axis is essential to identify the molecular rules that distinguish “beneficial” from “harmful” LPSs, an endeavor that stands at the frontier of microbiota-driven immunomodulation.

Friends or foes?

Resolving the chemistry of microbiota-derived LPSs might be essential for explaining why some gut microbes exert beneficial effects in certain contexts yet appear detrimental in others. Few cases illustrate this ambiguity as clearly as *Segatella copri* (formerly *Prevotella copri*), a dominant member of non-Westernized gut communities whose impact on human health remains highly debated. A recent study revealed that *S. copri* produces a heptose-deficient LOS, in which α -mannose replaces






Fig. 5 Structural variability in gut commensal LPS O-antigen moieties. Colors follow the symbol nomenclature for glycans to enable rapid identification of sugar configurations: green for *manno*-, blue for *gluco*-, and yellow for *galacto*-configured sugar units. Orange denotes xylose residues.

the canonical heptose as the first sugar linked to Kdo, forming a core OS essentially composed of glucose and mannose and featuring an intriguing α -1,2-linked terminal di-mannose at the non-reducing end (Fig. 6).⁶⁹ Moreover, its lipid A is extremely heterogenous, mono-phosphorylated and hypo-acylated (tetra and penta-acylated forms were identified) with minor species carrying an additional phosphate on the disaccharide backbone (Fig. 4). Even within the *Prevotella/Segatella* lineage, this architecture stands apart. For example, *P. intermedia* lipid A is mostly mono-phosphorylated and penta-acylated, with a relatively homogeneous profile,⁷⁰ whereas *P. denticola* displays a predominantly penta-acylated lipid A decorated with *P*ETn and a distinct combination of C17(3-OH), C16(3-OH), and C15:0 acyl chains (Fig. 4).⁷¹ Functionally, *S. copri* LOS behaves as a weak TLR4 agonist, yet it can dampen *E. coli*-induced NF- κ B activation and selectively preserve CD14⁺CD16⁺ monocytes.⁶⁹ This distinctive immunological signature suggests that *S. copri* LOS is not perceived as a danger signal but rather acts as a finely tuned modulator of host immunity. Its unusual chemical structure may therefore not elicit a strong alarm response, even at higher doses, but instead shape an attenuated, yet still immunologically competent, innate response. In this light, pinpointing the precise epitopes responsible for this peculiar behavior becomes essential, especially given the likely contribution of a coordinated crosstalk between TLR4 and mannose-recognizing lectins such as DC-SIGN and MBL. Deciphering this phenomenon may ultimately resolve the “*Segatella* paradox” by revealing when *S. copri* acts as a protective symbiont or as a potential driver of pathology.

A similar ambiguity emerges with *Paenalcigenes hominis*, a bacterium increasingly detected in the gut microbiota of

elderly individuals,⁷² and frequently linked to disorders involving the gut–brain axis.⁷³ Lee and colleagues demonstrated that *P. hominis* is associated with suppression of brain-derived neurotrophic factor, mediated by the activation of the TLR4-NF- κ B signaling pathway in microglia, the resident macrophages of the central nervous system.⁷³ These findings suggest that bacterial components, particularly LPSs, can translocate from the gut to the brain, triggering neuroinflammatory responses and establishing a mechanistic link between gut dysbiosis and cognitive decline.⁷⁴ How bacteria reach the brain remains an intriguing and largely unresolved question. However, it is hypothesized that outer membrane vesicles may play a key role in this interaction, as they can cross the blood–brain barrier and deliver immunologically active components like LPSs. A recent study showed that *P. hominis* produces an LPS whose O-antigen, built of rhamnose-glucosamine repeating units and decorated by nonstoichiometric acetylation (Fig. 5), adopts a flexible, loosely coiled conformation and forms highly hydrated aggregates, properties that likely influence receptor accessibility and immune signalling.⁷⁵ Moreover, consistent with its penta-acylated lipid A, *P. hominis* LPS activates TLR4 only weakly, while eliciting a moderate cytokine response in dendritic cells and engaging a distinct set of innate immune lectins, including ficolins and galectin-4.⁷⁵ These selective lectin-glycan interactions once again point to non-canonical recognition pathways and is particularly interesting in the case of *P. hominis* as it appears contradictory: while it exhibits structural features typically associated with low inflammatory potential, functional studies associate this bacterium to colitis and neuroinflammation. This data suggested that *P. hominis* might therefore exploit the peculiar composition of its LPS to






Fig. 6 Core OS structures from gut commensals. Colors follow the symbol nomenclature for glycans to enable rapid identification of sugar configurations: green for *manno*-, blue for *gluco*-, and yellow for *galacto*-configured sugar units. Kdo is depicted in yellow, while fucose residues are shown in red, in accordance with SNFG conventions.

sustain chronic low-grade inflammatory states rather than acute responses.

Among the most emblematic examples of the “beneficial LPS concept” is *Akkermansia muciniphila*, a mucin-degrading symbiont whose presence is consistently linked to improved metabolic health, enhanced intestinal barrier integrity, and expansion of regulatory T cells.⁷⁶ Remarkably, both live and pasteurized bacterial cells exert comparable, sometimes even superior, beneficial effects in mice and humans, a property largely attributed to the heat-stable outer membrane protein Amuc_1100, known to signal through TLR2.^{77,78} Yet *A. muciniphila*, as a Gram-negative member of the Verrucomicrobia, also produces LPSs, raising the question of how molecules classically associated with inflammation can coexist within a bacterium universally regarded as beneficial and considered a next-

generation probiotic. Recent structural investigations resolved this apparent contradiction by demonstrating that *A. muciniphila* strain MucT synthesizes two unusual LOSs, one of which bearing a strikingly large, non-repetitive core OS including a distinctive fucosylation pattern (Fig. 6, OS1 and OS2), coupled to an atypical lipid A moiety characterized by the presence of branched acyl chains and made up of a complex blend of mono- and bis-phosphorylated, tetra to hexa-acylated lipid A species.⁷⁹ Strikingly, this LOS engages both TLR4 and TLR2, with the TLR2 arm providing a compensatory, anti-inflammatory counterbalance to the weak canonical TLR4 activation.⁷⁹ The peculiar chemistry of its lipid A once again appears central to the LOS attenuated TLR4 agonism, while its extended carbohydrate region likely contributes to lectin-mediated modulation at the mucosal interface. A comparable paradigm emerges from



recent work on *Odoribacter splanchnicus*, another promising next-generation probiotic. Its exceptionally short LOS, enriched in unusual sugars such as D-4-O-(1-carboxylethyl)mannose (D-Man4Lac) and carrying a *Bacteroides*-like lipid A, forms supra-molecular aggregates encased in an extended oligosaccharide shell (Fig. 6).⁸⁰ This kind of “structural masking” sterically shields lipid A from the TLR4/MD-2 complex, thereby dampening receptor activation and favoring immune tolerance, epithelial preservation, and competition against more inflammatory *E. coli* LPS species.

Together, these examples further underline that within the gut microbiota, the boundary between “good” and “bad” LPS is not defined by taxonomy, but by chemistry. Only by dissecting the fine structural motifs, and the signaling pathways they engage, we can begin to predict whether an LPS will trigger inflammation, modulate immune response, or even serve as a therapeutic tool. In this sense, mapping the chemical logic of microbiota-derived LPSs is not an academic exercise; it is the key, instead, to decoding microbial behavior and engineering the next generation of immunomodulators.

Conclusions

The examples discussed in this Perspective collectively challenge the traditional view of LPSs as unidimensional pro-inflammatory triggers sensed exclusively through TLR4. Instead, gut-derived LPSs emerge as chemically diverse and functionally nuanced mediators that can span a continuum from strong agonism to near-immunological silence, and even active gut mucosal tolerance. This spectrum is not random: it is encoded in precise structural features of lipid A (acylation pattern, phosphorylation, charge distribution), in the architecture of the core OS and O-antigen, and in how these motifs are presented at the supramolecular level. A recurring theme across all species characterized thus far is that small chemical changes can produce disproportionately large shifts in immune outcome. Hypo-acylation and reduced phosphorylation of lipid A, zwitterionic or charge-masked saccharide regions, rare sugars such as galactofuranose or D-Man4Lac, and atypical aggregation states all converge to weaken or rewire canonical TLR4 signaling. These LPS structures, in fact, frequently engage a broader receptor repertoire, including TLR2, C-type lectins, galectins, ficolins, and other soluble or membrane-associated pattern-recognition molecules. The resulting responses are not simply “less inflammatory”, but qualitatively distinct, often favoring IL-10 production, Treg expansion, barrier maintenance, and tissue repair, or sustaining chronic low-grade inflammation instead of acute responses.¹

Another key message is that context matters: anatomical niche, host age, inflammatory tone, and microbial lifestyle (symbiont vs. pathobiont vs. opportunist) all shape both LPS chemistry and its interpretation by the host. The comparison between oral and intestinal *V. parvula* and the Peyer's patches-adapted *A. faecalis* underscores that LPSs are not static molecular patterns, but an evolvable interface optimized for specific ecological and immunological landscapes. Understanding this niche–structure–function axis will be essential for predicting

when a given LPS behaves as a beneficial signal, a tolerogenic buffer, or a driver of pathology. In this spirit, we hope that future work will increasingly focus on LPS heterogeneity not only across species, but within the same species isolated from different anatomical sites or even from different individuals. Such efforts may reveal personalized patterns of LPS chemistry that mirror, or even shape, individual immune tone. Ultimately, expanding LPS research into this intra-species and inter-individual dimension could lay the foundation for a new frontier in precision (glyco)immunology, where bacterial surface glycans are actionable targets for personalised interventions.

From a translational viewpoint, these insights open a double opportunity. On one hand, they highlight the potential of microbiota-derived LPSs as templates for next-generation immunomodulators, ranging from anti-inflammatory agents and adjuvants to mucosal vaccine platforms. Second, it highlights the need for diagnostic tools capable of distinguishing “good” from “bad” LPSs in complex samples, moving beyond crude LPS measurements toward molecularly resolved profiling of LPS mixtures. In this context, analytical advances are indispensable. While wet organic chemistry conjugated with NMR spectroscopy remain foundational for defining saccharide chemistry, high-resolution MS, still underused beyond lipid A, has the potential to transform LPS structural biology. Modern MS allows simultaneous interrogation of lipid and carbohydrate moieties with high accuracy, often requiring minimal material. When combined with ion mobility, MS can resolve isobaric species based on size, shape, and charge, generating drift-time maps that disentangle heterogeneous mixtures. Given the remarkable diversity of LPS structures even within single species, ion mobility-assisted MS is poised to become a central tool for deconvoluting this complexity. It also remains crucial to develop multiomic approaches capable of profiling lipid A and extended LPS structures in human-derived samples (*i.e.* stool, saliva, blood) and linking them to functional outputs.²⁵ Further validation in physiologically relevant *in vivo* systems is required, considering host physiology, microbial–microbial interactions, and environmental cues. While germ-free and TLR-knockout mice have provided valuable insights, their limitations are well known: several LPS chemotypes that are silent or antagonistic in mice remain stimulatory in humans due to species-specific differences in MD-2.^{81,82}

Moreover, large portions of the Gram-negative gut microbiota remain chemically unexplored. *Parabacteroides* species (*P. distasonis*, *P. goldsteinii*, *P. johnsonii*, *P. merdae*), reduced in obesity, metabolic syndrome, and IBD, still lack any structural definition of their LPSs.⁸³ The same holds for other abundant *Bacteroides* members, despite mounting functional evidence of immunoregulatory potential. Together, these blind spots reveal a simple truth: most immunologically relevant LPS structures in the gut microbiota remain undiscovered. Mapping this hidden chemical space will be essential to resolve conflicting phenotypes, identify novel immunomodulatory archetypes, and refine the notion of what makes an LPS “beneficial” or “pathogenic”.

Looking ahead, what the field still lacks, and what now appears within reach, is a unifying structure–function framework for gut commensal LPSs: experimentally grounded rules



linking discrete chemical motifs to reproducible immunological outputs across receptors, cell types, and anatomical sites. Building such a framework will require systematic comparisons across multiple gut Gram-negative species, integrating analytical chemistry, synthetic glycoengineering, biophysics, and immunology. Yet the potential payoff is enormous: (i) the ability to classify microbiota-derived LPSs as inflammatory, tolerogenic, or “tuned”; (ii) to predict their behavior *in vivo*; and ultimately (iii) to engineer synthetic LPS mimetics that recalibrate host immunity with unprecedented precision. In this sense, deciphering the chemical logic of gut-derived LPSs is far more than an exercise in structural curiosity. It is the necessary step to transform LPSs from just feared “endotoxins” into designable immunological tools that will help us understand, and eventually control, the thin line that separates microbial harm from microbial benefit.

Author contributions

Conceptualization, F. D. L.; writing – original draft, M. M., V. M. and F. D. L.; writing – review & editing, M. M., V. M., A. S., A. M. and F. D. L.; supervision, F. D. L.

Conflicts of interest

There are no conflicts to declare.

Data availability

Data for this perspective article are available from the references.

Acknowledgements

This work was supported by the European Research Council (ERC) under the Horizon Europe program under grant agreement no. 101039841 (DEBUGGING LPS) to F. D. L. and under grant agreement no. 101198490 (LPS-CODE) to A. M. It was also supported by the project “CLarIFY” and “GIVING” funded by the Italian Ministry of University and Research, PRIN MUR 2022 (2022SHW3KY) and PRIN MUR PNRR 2022 (P202293ZMC) to F. D. L. This work was also supported in part by the Italian Ministry of Foreign Affairs and International Cooperation (Italy Germany Science and Technology Cooperation – Call for joint research proposals for the years 2023–2025). This research was funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3—Call for tender no. 341 of 15 March 2022 of Italian Ministry of University and Research funded by the European Union—NextGenerationEU. Project code PE00000003, Concession Decree No. 1550 of 11 October 2022, adopted by the Italian Ministry of University and Research, CUP E63C22002030007, Project title “ON Foods—Research and Innovation Network on Food and Nutrition Sustainability, Safety and Security—Working ON Foods”.

References

- 1 F. Di Lorenzo, K. A. Duda, R. Lanzetta, A. Silipo, C. De Castro and A. Molinaro, *Chem. Rev.*, 2022, **122**, 15767–15821.
- 2 H. Zhu, C. S. Rollier and A. J. Pollard, *Expert Rev. Vaccines*, 2021, **20**, 1515–1538.
- 3 E. Könönen, S. Asikainen and H. Jousimies-Somer, *Oral Microbiol. Immunol.*, 1992, **7**, 28–31.
- 4 R. Luo, Y. Yao, Z. Chen and X. Sun, *Cell Commun. Signal.*, 2025, **23**, 142.
- 5 B. S. Park, D. H. Song, H. M. Kim, B. S. Choi, H. Lee and J. O. Lee, *Nature*, 2009, **458**, 1191–1195.
- 6 S. De Chiara, L. De Simone Carone, R. Cirella, E. Andretta, A. Silipo, A. Molinaro, M. Mercogliano and F. Di Lorenzo, *ChemMedChem*, 2025, **20**, e202400780.
- 7 T. Kawai and S. Akira, *Trends Mol. Med.*, 2007, **13**, 460–469.
- 8 E. R. Davenport, J. G. Sanders, S. J. Song, K. R. Amato, A. G. Clark and R. Knight, *BMC Biol.*, 2017, **15**, 127.
- 9 F. Di Lorenzo, C. De Castro, A. Silipo and A. Molinaro, *FEMS Microbiol. Rev.*, 2019, **43**, 257–272.
- 10 F. Di Lorenzo, C. De Castro, R. Lanzetta, M. Parrilli, A. Silipo and A. Molinaro, in *Carbohydrates in Drug Design and Discovery*, ed. J. Jimenez-Barbero, F. J. Canada and S. Martin-Santamaria, RSC, 2015, vol. 3, pp. 38–63.
- 11 P. Kumar, E. A. Schroder, M. V. S. Rajaram, E. N. Harris and L. P. Ganesan, *Cells*, 2024, **13**, 1590.
- 12 J. K. Kim, H. A. Jang, M. S. Kim, J. H. Cho, J. Lee, F. Di Lorenzo, L. Sturiale, A. Silipo, A. molinaro and B. L. Lee, *J. Biol. Chem.*, 2017, **292**, 19226–19237.
- 13 F. Di Lorenzo, A. Silipo, R. Lanzetta, M. Parrilli and A. Molinaro, in *Carbohydrate Chemistry: State of the Art and Challenges for Drug Development*, ed. Field, R. J. and Hill, H. A. O., World Scientific Publishing, 2015, vol. 3, pp. 57–89.
- 14 A. De Nicola, C. Montis, G. Donati, A. Molinaro, A. Silipo, A. Balestri, D. Berti, F. Di Lorenzo, Y.-L. Zhu and G. Milano, *Nanoscale*, 2023, **15**, 8988–8995.
- 15 F. Di Lorenzo, J. Billod, S. Martin-Santamaria, A. Silipo and A. Molinaro, *Eur. J. Org. Chem.*, 2017, **28**, 4055–4073.
- 16 A. Molinaro, O. Holst, F. Di Lorenzo, M. Callaghan, A. Nurisso, G. D'Errico, A. Zamyatina, F. Peri, R. Berisio, R. Jerala, J. Jimenez-Barbero, A. Silipo and S. Martin-Santamaria, *Chem.-Eur. J.*, 2015, **21**, 500–519.
- 17 J. R. Brestoff and D. Artis, *Nat. Immunol.*, 2013, **14**, 676–684.
- 18 M. Shabani, A. Ghoshehy, A. M. Mottaghi, Z. Chegini, A. Kerami, A. Shariati and M. Taati Moghadam, *Front. Cell. Infect. Microbiol.*, 2025, **15**, 1516010.
- 19 A. B. Shreiner, J. Y. Kao and V. B. Young, *Curr. Opin. Gastroenterol.*, 2015, **31**, 69–75.
- 20 K. Hou, Z. Wu, X. Chen, J. Wang, D. Zang, C. Xiao, D. Zhu, J. B. Koya, L. Wei, J. Li and Z. Chen, *Signal Transduct. Targeted Ther.*, 2022, **7**, 135.
- 21 S. S. Pillai, C. A. Gagnon, C. Foster and A. P. Ashraf, *J. Clin. Endocrinol. Metab.*, 2024, **109**, 2709–2719.
- 22 A. Vargas, B. L. Robinson, K. Houston, A. R. Vilela Sangay, M. Saadeh, S. D'Souza and D. A. Johnson, *Explor. Med.*, 2025, **6**, 1001275.



- 23 F. Sadeghpour Heravi, *Curr. Clin. Microbiol. Rep.*, 2024, **11**, 177–191.
- 24 A. Sai, G. B. Shetty, P. Shetty and H. L. Nanjeshgowda, Influence of gut microbiota on autoimmunity: A narrative review, *Brain Behav. Immun. Integr.*, 2024, **5**, 100046.
- 25 F. Di Lorenzo, L. Paparo, L. Pisapia, F. Oglio, M. D. Pither, R. Cirella, R. Nocerino, L. Carucci, A. Silipo, F. De Filippis, D. Ercolini, A. Molinaro and R. Berni Canani, *Front. Mol. Biosci.*, 2023, **10**, 1266293.
- 26 Z. Nádházi, A. Takáts, K. Offenmüller and L. Bertók, *Acta Microbiol. Immunol. Hung.*, 2002, **49**, 151–157.
- 27 E. d'Hennezel, S. Abubucker, L. O. Murphy and T. W. Cullen, *mSystems*, 2017, **2**, e00046–17.
- 28 K. Nishiyama, T. Yokoi, M. Sugiyama, R. Osawa, T. Mukai and N. Okada, *Front. Microbiol.*, 2021, **12**, 754819.
- 29 J. Tan, C. McKenzie, M. Potamitis, A. N. Thorburn, C. R. Mackay and L. Macia, *Adv. Immunol.*, 2014, **121**, 91–119.
- 30 J. H. Shin, G. Tillotson, T. N. Mackensie, C. A. Warren, H. M. Wexler and E. J. C. Goldstein, *Anaerobe*, 2024, **85**, 102819.
- 31 C. K. Fisher and P. Mehta, *PLoS One*, 2014, **9**, e102451.
- 32 H. M. Wexler, *Clin. Microbiol. Rev.*, 2007, **20**, 593–621.
- 33 F. Di Lorenzo, M. D. Pither, M. Martufi, I. Scarinci, J. Guzmán-Caldentey, E. Łakomic, W. Jachymek, S. C. M. Bruijns, S. M. Santamaria, J. Frick, Y. van Kooyk, F. Chiodo, A. Silipo, M. L. Bernardini and A. Molinaro, *ACS Cent. Sci.*, 2020, **6**, 1602–1616.
- 34 M. Hashimoto, F. Kirikae, T. Dohi, S. Adachi, S. Kusumoto, Y. Suda, T. Fujita, H. Naoki and T. Kirikae, *Eur. J. Biochem.*, 2002, **269**, 3715–3721.
- 35 E. T. Rietschel, T. Kirikae, F. U. Schade, U. Mamat, G. Schmidt, H. Loppnow, A. J. Ulmer, U. Zähringer, U. Seydel, F. Di Padova, M. Schreier and H. Brade, *FASEB J.*, 1994, **8**, 217–225.
- 36 A. Steimle, L. Michaelis, F. Di Lorenzo, T. Kliem, T. Münzner, J. K. Maerz, A. Schäfer, A. Lange, R. Parusel, K. Gronbach, K. Fuchs, A. Silipo, H. H. Öz, B. J. Pichler, I. B. Autenrieth, A. Molinaro and J. Frick, *Mol. Ther.*, 2019, **27**, 1974–1991.
- 37 M. D. Pither, A. Illiano, C. Pagliuca, A. Jacobson, G. Mantova, A. Stornaiuolo, R. Colicchio, M. Vitiello, G. Pinto, A. Silipo, M. A. Fischbach, P. Salvatore, A. Amoresano, A. Molinaro and F. Di Lorenzo, *Carbohydr. Polym.*, 2022, **297**, 120040.
- 38 M. Tiemblo Martín, M. Coccimiglio, E. Andretta, L. De Simone Carone, A. Bell, T. Gerpe-Amor, C. Di Carluccio, A. Molinaro, Y. Van Kooyk, N. Juge, F. Chiodo, F. Di Lorenzo and A. Silipo, *Carbohydr. Polym.*, 2025, **348**, 122833.
- 39 Z. Lin, H. Tang, L. Che, M. Chen, Z. Ye, X. Yang, L. Sun, K. H. Mayo, G. Tai, L. Cui and Y. Zhou, *Carbohydr. Polym.*, 2026, **373**, 124566.
- 40 G. Lugo-Villarino, A. Troegeler, L. Balboa, C. Lastrucci, C. Duval, I. Mercier, A. Bénard, F. Capilla, T. Al Saati, R. Poincloux, I. Kondova, F. A. W. Verreck, C. Cougoule, I. Maridonneau-Parini, M. del Carmen Sasiain and O. Neyrolles, *Front. Immunol.*, 2018, **9**, 1123.
- 41 H. Baek, S.-W. Yang, S. Kim, Y. Lee, H. Park, M. Park, B.-J. Jeon, H. Park, H.-S. Hwang, J.-Y. Kim, J.-H. Kim and Y.-S. Kang, *Int. J. Mol. Sci.*, 2025, **26**, 2329.
- 42 S. I. Gringhuis, J. den Dunnen, M. Litjens, M. van der Vlist and T. B. H. Geijtenbeek, *Nat. Immunol.*, 2009, **10**, 1081–1088.
- 43 T. B. H. Geijtenbeek, S. J. van Vliet, E. A. Koppel, M. Sanchez-Hernandez, C. M. J. E. Vandenbroucke-Grauls, B. Appelmelk and Y. van Kooyk, *J. Exp. Med.*, 2003, **197**, 7–17.
- 44 F. Nieto-Fabregat, Q. Zhu, C. Vivès, Y. Zhang, A. Marseglia, F. Chiodo, M. Thépaut, D. Rai, S. S. Kulkarni, F. Di Lorenzo, A. Molinaro, R. Marchetti, F. Fieschi, G. Xiao, B. Yu and A. Silipo, *JACS Au*, 2024, **4**, 697–712.
- 45 D. Rai, F. Nieto-Fabregat, R. Dikshit, M. Thépaut, F. Fieschi, A. Silipo and S. S. Kulkarni, *ACS Omega*, 2025, **10**, 51985–52000.
- 46 S. Francisco, J.-M. Billod, J. Merino, C. Punzón, A. Gallego, A. Arranz, S. Martin-Santamaria and M. Fresno, *Front. Immunol.*, 2022, **12**, 748303.
- 47 S. K. Mazmanian, C. H. Liu, A. O. Tzianabos and D. L. Kasper, *Cell*, 2005, **122**, 107–118.
- 48 C. L. Sears, A. L. Geis and F. Housseau, *J. Clin. Invest.*, 2014, **124**, 4166–4172.
- 49 E. B. Troy and D. L. Kasper, *Front. Biosci.*, 2010, **15**, 25–34.
- 50 T. Yang, J. Daugherti and D. L. Kasper, *bioRxiv*, 2024, preprint, DOI: [10.1101/2024.04.13.589361](https://doi.org/10.1101/2024.04.13.589361).
- 51 K. Kitamura, M. Sasaki, M. Matsumoto, H. Shironoya and K. Iida, *Immunol. Lett.*, 2021, **233**, 48–56.
- 52 A. K. Sulit, M. Daigneault, E. Allen-Vercoe, O. K. Silander, B. Hock, J. McKenzie, J. Person, F. A. Frizelle, S. Schmeier and R. Purcell, *npj Biofilms Microbiomes*, 2023, **9**, 59.
- 53 Q. He, M. Niu, J. Bi, N. Du, S. Liu, K. Yang, H. Li, J. Yao, Y. Du and Y. Duan, *Sci. Rep.*, 2023, **13**, 15842.
- 54 S. Hsieh, N. T. Porter, D. L. Donermeyer, S. Horvath, G. Strout, B. T. Saunders, N. Zhang, B. Zinselmeyer, E. C. Martens, T. S. Stappenbeck and P. M. Allen, *J. Immunol.*, 2020, **204**, 1035–1046.
- 55 A. N. Jacobson, B. P. Choudhury and M. A. Fischbach, *mBio*, 2018, **9**, e02289–17.
- 56 M. D. Pither, A. Silipo, F. Di Lorenzo and A. Molinaro, in *Comprehensive Glycoscience*, ed. N. Taniguchi and J. Barchi Jr, Elsevier, 2nd edn, 2021, vol. 5, pp. 233–249.
- 57 F. Di Lorenzo, L. Kubik, A. Oblak, N. I. Lorè, C. Cigana, R. Lanzetta, M. Parrilli, M. A. Hamad, A. De Soyza, A. Silipo, R. Jerala, A. Bragonzi, M. A. Valvano, S. Martin-Santamaria and A. Molinaro, *J. Biol. Chem.*, 2015, **290**, 21305–21319.
- 58 P. Zhou, D. Manoil, G. N. Belibasakis and G. A. Kotsakis, *Front. Oral Health*, 2021, **2**, 774115.
- 59 D. I. Poppleton, M. Duchateau, V. Hourdel, M. Matondo, J. Flechsler, A. Klingl, C. Beloin and S. Gribaldo, *Front. Microbiol.*, 2017, **8**, 1215.
- 60 C. V. Hughes, P. E. Kolenbrander, R. N. Andersen and L. V. Moore, *Appl. Environ. Microbiol.*, 1988, **54**, 1957–1963.
- 61 M. D. Pither, E. Andretta, G. Rocca, F. Balzarini, A. Matamoros-Recio, R. Colicchio, P. Salvatore, Y. Van Kooyk, A. Silipo, F. Granucci, S. Martin-Santamaria, F. Chiodo, A. Molinaro and F. Di Lorenzo, *Angew. Chem., Int. Ed.*, 2024, **63**, e202401541.



- 62 T. Obata, Y. Goto, J. Kunisawa, S. Sato, M. Sakamoto, H. Setoyama, T. Matsuki, K. Nonaka, N. Shibata, M. Gohda, Y. Kagiya, T. Nochi, Y. Yuki, Y. Fukuyama, A. Mukai, S. Shinzaki, K. Fujihashi, C. Sasakawa, H. Iijima, M. Goto, Y. Umesaki, Y. Benno and H. Kiyono, *Proc. Natl. Acad. Sci. U.S.A.*, 2010, **107**, 7419–7424.
- 63 N. Shibata, J. Kunisawa, K. Hosomi, Y. Fujimoto, K. Mizote, N. Kitayama, A. Shimoyama, H. Mimuro, S. Sato, N. Kishishita, K. J. Ishii, K. Fukase and H. Kiyono, *Mucosal Immunol.*, 2018, **11**, 693–702.
- 64 L. Ding, X. Chen, H. Cheng, T. Zhang and Z. Li, *Front. Chem.*, 2022, **10**, 974854.
- 65 A. Shimoyama, F. Di Lorenzo, H. Yamaura, K. Mizote, A. Palmigiano, M. D. Pither, I. Speciale, T. Uto, S. Masui, L. Sturiale, D. Garozzo, K. Hosomi, N. Shibata, Z. Kabayama, Y. Fujimoto, A. Silipo, J. Kunisawa, H. Kiyono, A. Molinaro and K. Fukase, *Angew. Chem., Int. Ed.*, 2021, **60**, 10023–10031.
- 66 K. Yoshii, K. Hosomi, A. Shimoyama, Y. Wang, H. Yamaura, T. Nagatake, H. Suzuki, H. Lan, H. Kiyono, K. Fukase and J. Kunisawa, *Microorganisms*, 2020, **8**, 1102.
- 67 Y. Wang, K. Hosomi, A. Shimoyama, K. Yoshii, H. Yamaura, T. Nagatake, T. Nishino, H. Kiyono, K. Fukase and J. Kunisawa, *Vaccines*, 2020, **8**, 395.
- 68 M. Martínez-López, S. Iborra, R. Conde-Garrosa, A. Mastrangelo, C. Danne, E. R. Mann, D. M. Reid, V. Gaboriau-Routhiau, M. Chaparro, M. P. Lorenzo, L. Minnerup, P. Saz-Leal, E. Slack, B. Kemp, J. P. Gisbert, A. Dzionek, M. J. Robinson, F. J. Rupérez, N. Cerf-Bensussan, G. D. Brown, D. Bernardo, S. LeibundGut-Landmann and D. Sancho, *Immunity*, 2019, **50**, 446–461.
- 69 L. De Simone Carone, G. Barra, R. Cirella, M. Ziaco, M. Mercogliano, F. Olmeo, E. Andretta, V. Mazziotti, C. Fusco, G. D'Ippolito, K. A. Duda, F. M. Farquharson, P. Louis, A. Fontana, A. Silipo, A. Molinaro and F. Chiodo, *Angew. Chem., Int. Ed.*, 2025, e202512947.
- 70 M. Hashimoto, Y. Asai, R. Tamai, T. Jinno, K. Umatani and T. Ogawa, *FEBS Lett.*, 2003, **543**, 98–102.
- 71 F. Di Lorenzo, A. Silipo, T. Matier, A. Hanuszkiewicz, J. S. Elborn, R. Lanzetta, L. Sturiale, A. Scamporrino, D. Garozzo, M. A. Valvano, M. M. Tunney and A. Molinaro, *Eur. J. Org. Chem.*, 2016, **2016**, 1732–1738.
- 72 S.-H. Park, K.-A. Kim, Y.-T. Ahn, J.-J. Jeong, C.-S. Huh and D.-H. Kim, *BMC Microbiol.*, 2015, **15**, 49.
- 73 K.-E. Lee, J.-K. Kim, S.-K. Han, D. Y. Lee, H.-J. Lee, S.-V. Yim and D.-H. Kim, *Microbiome*, 2020, **8**, 107.
- 74 H. J. Kim, H. Kim, J.-H. Lee and C. Hwangbo, *Immun. Ageing*, 2023, **20**, 67.
- 75 F. Nieto-Fabregat, M. Mercogliano, A. Cangiano, G. Vitiello, E. Andretta, L. A. Clifton, A. Vanacore, L. Buono, M. Asunción Campanero-Rhodes, D. Solís, C. Di Carluccio, G. Pecoraro, A. Molinaro, G. Smaldone, J.-K. Kim, D.-H. Kim, L. Paduano, F. Di Lorenzo and A. Silipo, *JACS Au*, 2025, **5**, 3311–3327.
- 76 F. Gao, C. Cheng, R. Li, Z. Chen, K. Tang and G. Du, *Front. Med.*, 2025, **12**, 1484656.
- 77 J. Wang, W. Xu, R. Wang, R. Cheng, Z. Tang and M. Zhang, *Food Funct.*, 2021, **12**, 3597–3610.
- 78 P. Garcia-Vello, H. L. P. Tytgat, J. Gray, J. Elzinga, F. Di Lorenzo, J. Biboy, D. Vollmer, C. De Castro, W. Vollmer, W. M. de Vos and A. Molinaro, *Glycobiology*, 2022, **32**, 712–719.
- 79 P. Garcia-Vello, H. L. P. Tytgat, J. Elzinga, M. Van Hul, H. Plover, M. Tiemblo-Martin, P. D. Cani, S. Nicolardi, M. Fragai, C. De Castro, F. Di Lorenzo, A. Silipo, A. Molinaro and W. M. de Vos, *Nat. Commun.*, 2024, **15**, 8411.
- 80 M. Tiemblo Martín, M. Mercogliano, K. Hiippala, L. De Simone Carone, M. A. Campanero-Rhodes, M. Masiello, A. Cangiano, A. Molinaro, L. Paduano, D. Solís, R. Satokari, F. Di Lorenzo and A. Silipo, *Chem. Sci.*, 2025, **17**(4), 2281–2294.
- 81 A. M. Hajjar, R. K. Ernst, E. S. Fortunato, A. S. Brasfield, C. S. Yam, L. A. Newlon, T. R. Kollmann, S. I. Miller and C. B. Wilson, *PLoS Pathog.*, 2002, **8**, e1002963.
- 82 J. Vašl, A. Oblak, T. T. Peternelj, J. Klett, S. Martin-Santamaria, T. L. Gioannini, J. P. Weiss and R. Jerala, *J. Immunol.*, 2016, **196**, 2309–2318.
- 83 Y. Cui, L. Zhang, X. Wang, Y. Yi, Y. Shan, B. Liu, Y. Zhou and X. Lü, *FEMS Microbiol. Lett.*, 2022, **369**, fnac072.

